Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
|
|
BIOCEPT INC (BIOC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/22/2023 |
8-K
| Quarterly results |
| 05/15/2023 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biocept Reports First Quarter 2023 Financial Results SAN DIEGO - Biocept, Inc. , a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update. “I'm exceptionally pleased with the progress being made with our FORESEE clinical trial, which is specifically designed to generate evidence of CNSide ™ 's clinical utility to support adoption into clinical care guidelines and further broaden physician use. Trial enrollment is running well in line with our plan, and we've now activated clinical sites in Dallas, Los Angeles and the San Francisco Bay Area,” said Samuel D. Riccitelli, Biocept's Chairman, and interim President and CEO. “In our quest to gain further physician and payor acceptan..." |
|
| 11/14/2022 |
8-K
| Quarterly results |
| 05/24/2022 |
8-K
| Quarterly results |
| 04/07/2022 |
8-K
| Quarterly results |
| 04/01/2022 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance SAN DIEGO - Biocept, Inc . , a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and cash equivalents as of December 31, 2021 of approximately $28 million. “Revenue reached a record high in 2021, up 123% over the prior year driven primarily by RT-PCR COVID-19 testing. As anticipated, we are currently experiencing a decline in COVID-19 testing demand as the unpredictable pandemic begins shifting to an endemic stage. Also, in the fourth quarter of 2021 we once again achieved sequential-quarter volume growth for CNSide ™ , our proprietary cerebrospinal fluid assay for the detection and monitoring of cancer involving the central nervous system,..." |
|
| 08/16/2021 |
8-K
| Quarterly results |
| 03/29/2021 |
8-K
| Quarterly results |
| 11/12/2020 |
8-K
| Quarterly results |
| 08/12/2020 |
8-K
| Quarterly results |
| 05/13/2020 |
8-K
| Quarterly results |
| 03/25/2020 |
8-K
| Quarterly results |
| 11/13/2019 |
8-K
| Quarterly results |
| 08/12/2019 |
8-K
| Quarterly results|
Docs:
|
"BIOCEPT, INC. CONDENSED BALANCE SHEETS December 31, June 30, 2018 2019 ASSETS Cash $ 3,423,373 $ 12,590,597 Accounts receivable, net 1,574,325 2,208,955 Inventories, net 587,222 605,472 Prepaid expenses and other current assets 425,961 586,267 TOTAL CURRENT ASSETS 6,010,881 15,991,291 FIXED ASSETS, NET 2,739,422 1,219,103 LEASE RIGHT-OF-USE ASSETS — 2,694,446 TOTAL ASSETS $ 8,750,303 $ 19,904,840 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES, NET $ 4,609,647 $ 5,821,870 NON-CURRENT LIABILITIES, NET 1,098,137 983,419 TOTAL LIABILITIES 5,707,784 6,805,289 SHAREHOLDERS’ EQUITY 3,042,519 13,099,551 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 8,750,303 $ 19,904,840 5 BIOCEPT, INC." |
|
| 05/08/2019 |
8-K
| Quarterly results |
| 11/13/2018 |
8-K
| Quarterly results |
| 05/15/2018 |
8-K
| Quarterly results |
| 11/09/2017 |
8-K
| Quarterly results |
| 08/10/2017 |
8-K
| Quarterly results |
| 05/11/2017 |
8-K
| Quarterly results |
| 03/07/2017 |
8-K
| Form 8-K - Current report |
| 11/09/2016 |
8-K
| Form 8-K - Current report |
| 08/02/2016 |
8-K
| Form 8-K - Current report |
| 05/12/2016 |
8-K
| Form 8-K - Current report |
| 03/09/2016 |
8-K
| Form 8-K - Current report |
| 11/05/2015 |
8-K
| Quarterly results |
| 08/10/2015 |
8-K
| Quarterly results |
| 05/12/2015 |
8-K
| Quarterly results |
| 03/09/2015 |
8-K
| Quarterly results |
| 11/13/2014 |
8-K
| Quarterly results |
|
|